Scholar Rock Holding Corp

NASDAQ:SRRK USA Biotechnology
Market Cap
$4.15 Billion
Market Cap Rank
#3654 Global
#2368 in USA
Share Price
$40.71
Change (1 day)
+1.12%
52-Week Range
$24.47 - $48.00
All Time High
$68.02
About

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to deve… Read more

Scholar Rock Holding Corp (SRRK) - Net Assets

Latest net assets as of September 2025: $245.00 Million USD

Based on the latest financial reports, Scholar Rock Holding Corp (SRRK) has net assets worth $245.00 Million USD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($411.72 Million) and total liabilities ($166.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $245.00 Million
% of Total Assets 59.51%
Annual Growth Rate N/A
5-Year Change 41.36%
10-Year Change N/A
Growth Volatility 55.15

Scholar Rock Holding Corp - Net Assets Trend (2016–2024)

This chart illustrates how Scholar Rock Holding Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Scholar Rock Holding Corp (2016–2024)

The table below shows the annual net assets of Scholar Rock Holding Corp from 2016 to 2024.

Year Net Assets Change
2024-12-31 $368.63 Million +63.68%
2023-12-31 $225.22 Million -13.46%
2022-12-31 $260.24 Million +51.23%
2021-12-31 $172.07 Million -34.01%
2020-12-31 $260.77 Million +130.97%
2019-12-31 $112.90 Million +5.89%
2018-12-31 $106.62 Million +299.21%
2017-12-31 $-53.52 Million -78.25%
2016-12-31 $-30.03 Million --

Equity Component Analysis

This analysis shows how different components contribute to Scholar Rock Holding Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 89018500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $94.00K 0.03%
Other Comprehensive Income $160.00K 0.04%
Other Components $1.29 Billion 350.24%
Total Equity $368.63 Million 100.00%

Scholar Rock Holding Corp Competitors by Market Cap

The table below lists competitors of Scholar Rock Holding Corp ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Scholar Rock Holding Corp's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 225,218,000 to 368,634,000, a change of 143,416,000 (63.7%).
  • Net loss of 246,294,000 reduced equity.
  • New share issuances of 324,414,000 increased equity.
  • Other comprehensive income increased equity by 68,000.
  • Other factors increased equity by 65,228,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-246.29 Million -66.81%
Share Issuances $324.41 Million +88.0%
Other Comprehensive Income $68.00K +0.02%
Other Changes $65.23 Million +17.69%
Total Change $- 63.68%

Book Value vs Market Value Analysis

This analysis compares Scholar Rock Holding Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 11.03x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 $-1.68 $40.71 x
2017-12-31 $-2.99 $40.71 x
2018-12-31 $6.81 $40.71 x
2019-12-31 $4.10 $40.71 x
2020-12-31 $8.48 $40.71 x
2021-12-31 $4.69 $40.71 x
2022-12-31 $4.37 $40.71 x
2023-12-31 $2.96 $40.71 x
2024-12-31 $3.69 $40.71 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Scholar Rock Holding Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -66.81%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.29x
  • Recent ROE (-66.81%) is below the historical average (-43.39%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 0.00% -4276.25% 0.01x 0.00x $-13.20 Million
2017 0.00% 0.00% 0.00x 0.00x $-19.64 Million
2018 -46.26% 0.00% 0.00x 1.70x $-59.99 Million
2019 -44.02% -242.52% 0.10x 1.74x $-60.99 Million
2020 -32.59% -551.79% 0.04x 1.49x $-111.07 Million
2021 -76.59% -700.46% 0.06x 1.77x $-149.01 Million
2022 -50.59% -396.61% 0.09x 1.38x $-157.67 Million
2023 -73.61% 0.00% 0.00x 1.38x $-188.31 Million
2024 -66.81% 0.00% 0.00x 1.29x $-283.16 Million

Industry Comparison

This section compares Scholar Rock Holding Corp's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $59,082,939
  • Average return on equity (ROE) among peers: -341.19%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Scholar Rock Holding Corp (SRRK) $245.00 Million 0.00% 0.68x $3.39 Billion
Aadi Bioscience Inc (AADI) $-124.24K 0.00% 0.00x $17.03 Million
America Great Health (AAGH) $-992.37K 0.00% 0.00x $2.12 Million
Ascentage Pharma Group International (AAPG) $70.63 Million -1310.51% 34.40x $2.25 Billion
Aardvark Therapeutics, Inc. Common Stock (AARD) $-27.92 Million 0.00% 0.00x $59.18 Million
ABIVAX Société Anonyme (AAVXF) $196.01 Million -75.37% 0.67x $377.86 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $738.02 Million
Abeona Therapeutics Inc (ABEO) $489.00K -1919.02% 38.85x $202.79 Million
Acumen Pharmaceuticals Inc (ABOS) $188.78 Million -22.70% 0.04x $108.65 Million
Abpro Holdings, Inc. (ABP) $-22.46 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $176.18 Million -62.76% 0.23x $345.85 Million